DBV Technologies SA – (DBVT) Lowered to “Hold” at Zacks Investment Research
DBV Technologies SA – (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other equities research analysts have also weighed in on DBVT. Societe Generale raised DBV Technologies SA – from a “hold” rating to a “buy” rating in a report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $47.00 price objective on shares of DBV Technologies SA – in a report on Thursday. Leerink Swann reaffirmed an “outperform” rating on shares of DBV Technologies SA – in a report on Wednesday, March 15th. Finally, Natixis raised DBV Technologies SA – from a “neutral” rating to a “buy” rating in a report on Friday, February 17th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $46.50.
This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/dbv-technologies-sa-dbvt-lowered-to-hold-at-zacks-investment-research.html
DBV Technologies SA – (NASDAQ:DBVT) traded up 1.55% during midday trading on Monday, hitting $35.42. The stock had a trading volume of 103,040 shares. DBV Technologies SA – has a 12-month low of $27.02 and a 12-month high of $37.98. The stock has a 50-day moving average price of $35.33 and a 200 day moving average price of $35.61. The firm’s market cap is $1.63 billion.
Your IP Address:
Hedge funds and other institutional investors have recently modified their holdings of the company. Royal Bank of Canada boosted its stake in DBV Technologies SA – by 115.8% in the second quarter. Royal Bank of Canada now owns 4,100 shares of the company’s stock valued at $133,000 after buying an additional 2,200 shares during the last quarter. TD Asset Management Inc. purchased a new stake in DBV Technologies SA – during the third quarter valued at approximately $272,000. Castleark Management LLC boosted its stake in DBV Technologies SA – by 136.9% in the fourth quarter. Castleark Management LLC now owns 9,690 shares of the company’s stock valued at $340,000 after buying an additional 5,600 shares during the last quarter. Sectoral Asset Management Inc purchased a new stake in DBV Technologies SA – during the third quarter valued at approximately $1,428,000. Finally, Norges Bank purchased a new stake in DBV Technologies SA – during the fourth quarter valued at approximately $1,757,000. Hedge funds and other institutional investors own 48.96% of the company’s stock.
About DBV Technologies SA –
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.